Figure 5

Effect of systemic or local PFC nepicastat administration on DAT-KO hyperactivity. (A) Locomotor activity (cm/5 min) of hyperactive DAT-KO mice was recorded for a 30 min baseline measurement followed by systemic injection with nepicastat or vehicle, and an additional 120 min of post-injection activity was recorded. (B) Total distance traveled (cm/150 min) was calculated. n = 6–12 mice per group. Pairwise comparisons using Two Way ANOVA, ****p < 0.0001. DAT-KO mice were infused with vehicle or 4ug/0.5ul of nepicastat in the PFC. (C) Locomotor activity (cm/5 min) was recorded for a 30 min baseline and an additional post-infusion recording of 120 min. (D) Total distance traveled (AUC) was calculated for baseline (cm/30 min) and post-infusion (cm/120 min). Pairwise comparisons using Two-way ANOVA, F (4, 52) = 2.973, *p < 0.05. (E) DAT-KO PFC tissue was analyzed upon nepicastat (Nep) i.p. injection for NE, DA or 5-HT levels by HPLC. P-values calculated using Two-way ANOVA, F (2, 18) = 1016, Nep compared to vehicle (veh) treated, n = 4.